Drug products: Altargo®
ATC code: D06AX13
The efficacy of retapamulin in treatment of skin infections is similar in men and women. However, studies of dosing and adverse events with a relevant gender analysis are scarce.
Pharmacokinetics an dosing
No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of retapamulin have been found.
The efficacy of topical retapamulin in patients with secondarily infected traumatic lesions was evaluated in a randomized, double-blind, placebo-controlled study (219 men, 140 women; all ages >2 months). Men/boys and women/girls receiving retapamulin had similar success rates, measured as clinical improvement . Also, the original manufacturer report similar responses to retapamulin in treatment of impetigo in both sexes in clinical studies [2, 3].
Clinical trials of retapamulin safety have not reported sex-stratified results [1, 4].
Reproductive health issues
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Date of litterature search: 2016-03-29
- Tomayko JF, Li G, Breton JJ, Scangarella-Oman N, Dalessandro M, Martin M. The safety and efficacy of topical retapamulin ointment versus placebo ointment in the treatment of secondarily infected traumatic lesions: a randomized, double-blind superiority study. Adv Skin Wound Care. 2013;26:113-21. PubMed
- ALTABAX ( retapamulin). DailyMed [www]. US National Library of Medicine. [updated 2015-04-20, cited 2016-03-29]. länk
- ALTABAX ( retapamulin). Labeling. U.S. Food and Drug Administration (FDA); 2012.
- Koning S, van der Wouden JC, Chosidow O, Twynholm M, Singh KP, Scangarella N et al. Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double-blind multicentre placebo-controlled trial. Br J Dermatol. 2008;158:1077-82. PubMed
- Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-05-30.] Socialstyrelsens statistikdatabas
Reviewed by: Mia von Euler
Approved by: Karin Schenck-Gustafsson